A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

Inclusion Criteria: * Healthy participants 18 to 45 years of age * POCBP with intact ovarian function by medical history and history of regular menstrual cycles for the past 12 * Body weight greater than or equal to (≥) 45 kilograms (kg) and Body mass index (BMI) within the range of 18.5 to 32.0 kg/m2 * Female participants of childbearing potential must use approved highly effective non-hormonal forms of birth control. * Capable of giving signed informed consent. Exclusion Criteria: * History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs. * Lymphoma, leukemia, or any malignancy within the past 5 years with some exceptions * Breast cancer or in remission within the past 10 years. * Current or chronic history of liver disease or known hepatic or biliary abnormalities with some exceptions. * Any personal and/or family history of thrombophilia or blood clots * Medical history of cardiac arrhythmias or cardiac disease or a family and personal history of long QT syndrome. * History of seizure(s). * Any known or suspected pre-existing psychiatric condition, including depression, anxiety, and/or insomnia/sleep disturbances. * Subjects with history of drug hypersensitivity, delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions will be excluded. * Participant is mentally or legally incapacitated. Prior/Concomitant Therapy • Any warnings and contraindications that apply based on Loestrin prescribing information. Prior/Concurrent Clinical Study Experience * Exposure to more than 4 new investigational products (including long-acting investigational products) within 12 months prior to the first dosing day. * Current enrollment or past participation in another investigational study in which an investigational intervention was administered within the last 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) before signing of consent (or screening) any other clinical study. * Participant has donated or lost blood (\>500 millilitres (mL)) or blood products within 2 months (56-day period) prior to Day -1 admission or has donated plasma within 30 days prior to first OC administration. * Current enrollment or past participation in this clinical study. Unwillingness or inability to follow the procedures outlined in the protocol. * Positive Human immunodeficiency virus 1 (HIV-1) antibody test. * Pregnant at screening) or lactating. * POCBP who are unwilling or unable to use an appropriate non-hormonal method of highly effective contraception from at least Day 1 of Treatment Period 1 until 14 days after the last dose of VH4524184. * Regular alcohol consumption within 6 months prior to the study defined as an average weekly intake of \>7 units for females. One unit is equivalent to 8 grams (g) of alcohol: a half-pint (\~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits. * Regular use of known drugs of abuse.